Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 54

1.

The evolving role of biologics in the treatment of pediatric psoriasis.

Luu M, Cordoro KM.

Skin Therapy Lett. 2013 Feb;18(2):1-4.

2.

Sequential use of biologics in the treatment of moderate-to-severe plaque psoriasis.

Leman J, Burden AD.

Br J Dermatol. 2012 Nov;167 Suppl 3:12-20. doi: 10.1111/j.1365-2133.2012.11209.x. Review.

PMID:
23082811
3.

Use of biologic agents in pediatric psoriasis.

Marji JS, Marcus R, Moennich J, Mackay-Wiggan J.

J Drugs Dermatol. 2010 Aug;9(8):975-86. Review.

PMID:
20684148
4.

Infections associated with the use of tumor necrosis factor-α inhibitors in psoriasis.

Tan X, Balkrishnan R, Feldman SR.

J Drugs Dermatol. 2013 Mar;12(3):e41-5. Review.

PMID:
23545925
5.

Effective and sustainable biologic treatment of psoriasis: what can we learn from new clinical data?

Langley RG.

J Eur Acad Dermatol Venereol. 2012 Mar;26 Suppl 2:21-9. doi: 10.1111/j.1468-3083.2011.04412.x. Review.

PMID:
22356632
6.
7.

Management of severe psoriasis with TNF antagonists. Adalimumab, etanercept and infliximab.

Mossner R, Reich K.

Curr Probl Dermatol. 2009;38:107-36. doi: 10.1159/000232307. Epub 2009 Jul 28. Review.

PMID:
19710553
8.

Anti-TNF agents for the treatment of psoriasis.

Kircik LH, Del Rosso JQ.

J Drugs Dermatol. 2009 Jun;8(6):546-59. Review.

PMID:
19537380
9.

Tumor necrosis factor antagonists in the therapy of psoriasis.

Mössner R, Schön MP, Reich K.

Clin Dermatol. 2008 Sep-Oct;26(5):486-502. doi: 10.1016/j.clindermatol.2007.10.030. Review.

PMID:
18755367
10.

[Psoriasis updates].

Boulinguez S.

Ann Dermatol Venereol. 2010 May;137(5 Suppl 1):1-4. doi: 10.1016/S0151-9638(10)70015-6. Review. French. No abstract available.

PMID:
20510173
11.

Switching to adalimumab in patients with moderate to severe psoriasis who have failed on etanercept: a retrospective case cohort study.

Woolf RT, Smith CH, Robertson K, Barker JN.

Br J Dermatol. 2010 Oct;163(4):889-92. doi: 10.1111/j.1365-2133.2010.09893.x. Epub 2010 Jul 28. Review. No abstract available.

PMID:
20854408
12.

[Long-term psoriasis treatment].

Jullien D, Battistella M.

Ann Dermatol Venereol. 2011 Feb;138(2 Suppl 1):H15-8. doi: 10.1016/S0151-9638(11)70058-8. Review. French. No abstract available.

PMID:
21396519
13.

The status of biologic therapies in the treatment of moderate to severe psoriasis.

Menter A.

Cutis. 2009 Oct;84(4 Suppl):14-24. Review.

PMID:
19916298
14.

Pediatric psoriasis: updates in biologic therapies.

Sukhatme SV, Gottlieb AB.

Dermatol Ther. 2009 Jan-Feb;22(1):34-9. doi: 10.1111/j.1529-8019.2008.01214.x. Review.

PMID:
19222515
15.

Etanercept provides an effective, safe and flexible short- and long-term treatment regimen for moderate-to-severe psoriasis: a systematic review of current evidence.

Strohal R, Chimenti S, Vena GA, Girolomoni G.

J Dermatolog Treat. 2013 Jun;24(3):199-208. doi: 10.3109/09546634.2012.713462. Epub 2012 Nov 10. Review.

PMID:
22812568
16.

Efficacy and safety of ustekinumab and etanercept for the treatment of psoriasis.

Uhlenhake EE, Feldman SR.

Expert Opin Biol Ther. 2010 Jul;10(7):1105-12. doi: 10.1517/14712598.2010.487061. Review.

PMID:
20446825
17.

[Tolerance of biological agents in children].

Bader-Meunier B.

Arch Pediatr. 2010 Jun;17(6):962-3. doi: 10.1016/S0929-693X(10)70199-8. Review. French. No abstract available.

PMID:
20654981
18.

Safety of anti-TNFα agents in the treatment of psoriasis and psoriatic arthritis.

Girolomoni G, Altomare G, Ayala F, Berardesca E, Calzavara-Pinton P, Chimenti S, Peserico A, Puglisi Guerra A, Vena GA.

Immunopharmacol Immunotoxicol. 2012 Aug;34(4):548-60. doi: 10.3109/08923973.2011.653646. Epub 2012 Feb 2. Review.

PMID:
22296031
19.

Detection and management of latent tuberculosis infections before biologic therapy for psoriasis.

Amerio P, Amoruso G, Bardazzi F, Campanati A, Cassano N, Conti A, Gisondi P, Guarneri C, Mazzotta A, Piaserico S, Prestinari F, Prignano F, Zane C, de Simone C.

J Dermatolog Treat. 2013 Aug;24(4):305-11. doi: 10.3109/09546634.2011.654107. Epub 2012 Jan 31.

PMID:
22208431
20.

Benefit-risk assessment of tumour necrosis factor antagonists in the treatment of psoriasis.

Langley RG, Strober BE, Gu Y, Rozzo SJ, Okun MM.

Br J Dermatol. 2010 Jun;162(6):1349-58. doi: 10.1111/j.1365-2133.2010.09707.x. Epub 2010 Apr 14. Review.

PMID:
20394634

Supplemental Content

Support Center